Reaction

Physical Deconditioning reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,472 reports · 91 co-occurring drugs

As of the last recalculation, Physical Deconditioning appears in 2,472 FAERS reports alongside 91 co-occurring drug terms. The strongest observed disproportionality signal is TOFACITINIB CITRATE (PRR 108.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tofacitinib Citrate	158	108.3	109.6
Tramadol Hydrochloride	252	62.7	63.1
Esomeprazole Magnesium Capsule, Delayed Release	95	57.3	57.7
Esomeprazole Magnesium Delayed Release Capsules	95	57.3	57.7
Esomeprazole Magnesium Dihydrate	95	57.0	57.4
Valsartan Oral	264	45.7	45.9
Esomeprazole	294	45.2	45.4
Venlafaxine	295	39.2	39.4
Escitalopram Oxalate	295	38.5	38.7
Valsartan	272	24.4	24.4
Fluoxetine Hydrochloride	292	21.7	21.8
Venlafaxine Hydrochloride	298	21.4	21.5
Escitslopram	138	21.1	21.1
Febuxostat Tablets 40 Mg	25	20.9	20.9
Febuxostat Tablets 80 Mg	25	20.9	20.9
Escitalopram	303	20.6	20.6
Axicabtagene Ciloleucel	23	19.8	19.8
Romosozumab-Aqqg	31	19.5	19.5
Amikacin	33	16.5	16.5
Esomeprazole Magnesium	328	13.5	13.5
Apalutamide	18	13.0	13.0
Febuxostat	25	12.7	12.7
Nintedanib	46	12.6	12.6
Suvorexant	19	12.4	12.4
Acetaminophen Tablet Extended Release	325	12.2	12.2
Pain Reliever	325	12.2	12.2
Acetaminophen 500Mg	325	12.2	12.2
Abaloparatide	39	11.3	11.3
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	37	10.2	10.2
Tolvaptan	17	9.9	9.9
Fluoxetine	75	9.7	9.7
Amlodipine	276	9.6	9.6
Magnesium Oxide	46	9.4	9.4
Pitavastatin Calcium	10	8.3	8.3
Teduglutide	13	8.2	8.2
Regorafenib	11	8.0	8.0
Tofacitinib	163	7.9	7.9
Umeclidinium	8	7.5	7.5
Acetaminophen	344	7.4	7.4
Lubiprostone	8	7.1	7.1
Canakinumab	9	7.0	7.0
Ursosiol	16	7.0	7.0
Encorafenib	8	6.8	6.8
Pembrolizumab	80	6.6	6.6
Atovaquone	6	6.3	6.3
Selexipag	19	6.2	6.2
Ursodiol	16	6.2	6.2
Rasagiline Mesylate	8	6.1	6.1
Terazosin Hydrochloride	6	5.7	5.7
Ravulizumab	9	5.6	5.6
Nivolumab	62	5.5	5.5
Durvalumab	13	5.4	5.4
Dutasteride	5	5.2	5.2
Ipilimumab	26	5.1	5.1
Linagliptin	11	5.1	5.1
Cenobamate	5	5.1	5.1
Azacitidine For	10	4.6	4.6
Dapagliflozin	16	4.3	4.3
Cabozantinib	24	4.2	4.2
Vibegron	4	4.2	4.2
Obinutuzumab	8	4.1	4.1
Rotigotine	7	4.1	4.1
Icosapent Ethyl	4	4.0	4.0
Paliperidone Palmitate	15	3.9	3.9
Empagliflozin	31	3.9	3.9
Treprostinil	57	3.9	3.9
Siponimod	4	3.8	3.8
Mirabegron	17	3.7	3.7
Azacitidine	12	3.4	3.4
Prasugrel Hydrochloride	4	3.3	3.3
Sacubitril And Valsartan	45	3.3	3.3
Atezolizumab	15	3.3	3.3
Paliperidone	9	3.3	3.3
Cetuximab	12	3.2	3.2
Budesonide, Glycopyrrolate, And Formoterol Fumarate	4	3.2	3.2
Lurasidone Hydrochloride	8	3.2	3.2
Lenvatinib	12	3.1	3.1
Abemaciclib	7	3.0	3.0
Vigabatrin	5	2.9	2.9
Sarilumab	9	2.9	2.9
Enzalutamide	18	2.6	2.6
Brexpiprazole	5	2.5	2.5
Fam-Trastuzumab Deruxtecan-Nxki	3	2.5	2.5
Ethyl Alcohol	8	2.5	2.5
Abiraterone	4	2.5	2.5
Olaparib	6	2.4	2.4
Onabotulinumtoxina	22	2.4	2.4
Abiraterone Acetate	11	2.3	2.3
Osimertinib	8	2.1	2.1
Valbenazine	6	2.0	2.0
Pomalidomide	15	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.